Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Thoracic 1

Conditions

Small Cell Lung Carcinoma 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Osteosarcoma 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Pathologic Complete Response 1Neutropenia 1Neoplasms 1NSCLC 1Myelosuppression 1Limited Stage Small Cell Lung Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × trilaciclib × Clear all
NCT06027268 2026-04-22

ToPCourT

Wake Forest University Health Sciences

Phase 2 Active not recruiting
36 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

G1 Therapeutics, Inc.

Phase 3 Completed
194 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04863248 2023-04-14

PRESERVE 4

G1 Therapeutics, Inc.

Phase 2 Terminated
10 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02978716 2022-03-23

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

G1 Therapeutics, Inc.

Phase 2 Terminated
102 enrolled 51 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡